CTHRC1 is associated with BRAF(V600E) mutation and correlates with prognosis, immune cell infiltration, and drug resistance in colon cancer, thyroid cancer, and melanoma. (2024). Biomolecules and Biomedicine, 25(1), 42–61. https://doi.org/10.17305/bb.2024.10397